[Chinese expert consensus on the diagnosis and treatment of plasmablastic lymphoma (2025)]

Plasmablastic lymphoma (PBL) originates from activated B cells in the terminal differentiation stage of the germinal centers. PBL is characterized by unique clinical, pathological, and molecular features, demonstrating high aggressiveness and poor prognosis. It exhibits a low incidence and a challenging diagnosis, with a lack of standardized treatment protocols. To improve the understanding of PBL among clinical physicians in China and enhance diagnostic and treatment levels, which will facilitate the initiation of multicenter clinical research, the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) have organized relevant experts to formulate this consensus.